Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Gains from Investment Securities (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Gains from Investment Securities for 16 consecutive years, with -$40000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 99.81% year-over-year to -$40000.0, compared with a TTM value of -$21.2 million through Sep 2025, down 198.91%, and an annual FY2023 reading of $275000.0, down 97.61% over the prior year.
  • Gains from Investment Securities was -$40000.0 for Q4 2025 at Amicus Therapeutics, down from $17000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $20.1 million in Q3 2024 and bottomed at -$21.2 million in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $913950.0, with a median of $294000.0 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities plummeted 45577.78% in 2021, then skyrocketed 6561.75% in 2024.
  • Year by year, Gains from Investment Securities stood at -$8.2 million in 2021, then soared by 104.53% to $371000.0 in 2022, then plummeted by 47.98% to $193000.0 in 2023, then crashed by 11082.9% to -$21.2 million in 2024, then skyrocketed by 99.81% to -$40000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for FOLD at -$40000.0 in Q4 2025, $17000.0 in Q3 2025, and $1.2 million in Q2 2025.